Foresite returns to the SPAC well, as investors wonder how long the run can last

Jason Mast

Editor

Six months after launching his first biotech SPAC, Foresite’s Jim Tananbaum has started a second. On Tuesday, the longtime life science investor filed to raise …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Foresite returns to the SPAC well, as investors wonder how long the run can last

Jason Mast

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Merck KGaA closes in on SpringWorks deal at $3.5B price point

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Fore­site re­turns to the SPAC well, as in­vestors won­der how long the run can last

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Foresite returns to the SPAC well, as investors wonder how long the run can last